Terms: = Lung cancer AND KIF5B, ENSG00000170759, 3799, P33176, UKHC, KNS1, KNS, KINH AND Prognosis
13 results:
1. Comparison of gene mutation profile in different lung adenocarcinoma subtypes by targeted next-generation sequencing.
Zhang S; Dong P; Pan Z; Chen Q; Zhu J; Mao Z
Med Oncol; 2023 Nov; 40(12):349. PubMed ID: 37935925
[TBL] [Abstract] [Full Text] [Related]
2. Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer.
Gao M; Zhang X; Yan H; Sun D; Yang X; Yuan F; Ju Y; Wang L; Wang J; Zhao W; Zhang D; Li L; Xu X; Ma J; Hu Y; Zhang X
Support Care Cancer; 2023 Nov; 31(12):671. PubMed ID: 37924363
[TBL] [Abstract] [Full Text] [Related]
3. Combined large cell neuroendocrine carcinoma, lung adenocarcinoma, and squamous cell carcinoma: a case report and review of the literature.
Zhu Z; Liu Y; Xu H; Ning H; Xia Y; Shen L
J Cardiothorac Surg; 2023 Aug; 18(1):254. PubMed ID: 37653509
[TBL] [Abstract] [Full Text] [Related]
4. Pathological characteristics and tumour immune microenvironment of lung malignancies with RET rearrangement.
Gao QY; Xiao FM; Lin XC; Chen YQ; Li YF; Lu C; Su JW; Tan QQ; Zhang CY; Yang J; Wu YL; Chen HJ; Yang JJ
Cancer Treat Res Commun; 2023; 35():100707. PubMed ID: 37121144
[TBL] [Abstract] [Full Text] [Related]
5. Partial response to pralsetinib in an advanced pulmonary sarcomatoid carcinoma patient harboring a kif5b-RET rearrangement: a case report.
Wu Y; Yan Z; Pan J; Chang X; Huang B; Luo D; Meng R; Shi H; Fan J; Nie X
World J Surg Oncol; 2022 Dec; 20(1):386. PubMed ID: 36471407
[TBL] [Abstract] [Full Text] [Related]
6. RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
Wang C; Zhang Z; Sun Y; Wang S; Wu M; Ou Q; Xu Y; Chen Z; Shao Y; Liu H; Hou P
J Transl Med; 2022 Sep; 20(1):390. PubMed ID: 36059009
[TBL] [Abstract] [Full Text] [Related]
7. Unique Genetic Characteristics and Clinical prognosis of Female Patients with lung cancer Harboring RET Fusion Gene.
Qiu Z; Ye B; Wang K; Zhou P; Zhao S; Li W; Tian P
Sci Rep; 2020 Jun; 10(1):10387. PubMed ID: 32587276
[TBL] [Abstract] [Full Text] [Related]
8. Analysis of Cell-Free DNA from 32,989 Advanced cancers Reveals Novel Co-occurring Activating
Rich TA; Reckamp KL; Chae YK; Doebele RC; Iams WT; Oh M; Raymond VM; Lanman RB; Riess JW; Stinchcombe TE; Subbiah V; Trevarthen DR; Fairclough S; Yen J; Gautschi O
Clin Cancer Res; 2019 Oct; 25(19):5832-5842. PubMed ID: 31300450
[TBL] [Abstract] [Full Text] [Related]
9. Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer.
Gao HF; Yang JJ; Chen ZH; Zhang XC; Yan HH; Guo WB; Zhou Q; Gou LY; Dong ZY; Wu YL
Oncotarget; 2016 Jun; 7(26):39535-39543. PubMed ID: 27213587
[TBL] [Abstract] [Full Text] [Related]
10. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
Wang R; Pan Y; Li C; Zhang H; Garfield D; Li Y; Ye T; Hu H; Luo X; Li H; Zhang Y; Zhang J; Zhou X; Shen L; Pao W; Sun Y; Chen H
J Thorac Oncol; 2014 Jun; 9(6):760-8. PubMed ID: 24481316
[TBL] [Abstract] [Full Text] [Related]
11. kif5b-RET fusions in Chinese patients with non-small cell lung cancer.
Cai W; Su C; Li X; Fan L; Zheng L; Fei K; Zhou C
Cancer; 2013 Apr; 119(8):1486-94. PubMed ID: 23378251
[TBL] [Abstract] [Full Text] [Related]
12. RET, ROS1 and ALK fusions in lung cancer.
Takeuchi K; Soda M; Togashi Y; Suzuki R; Sakata S; Hatano S; Asaka R; Hamanaka W; Ninomiya H; Uehara H; Lim Choi Y; Satoh Y; Okumura S; Nakagawa K; Mano H; Ishikawa Y
Nat Med; 2012 Feb; 18(3):378-81. PubMed ID: 22327623
[TBL] [Abstract] [Full Text] [Related]
13. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer.
Salido M; Pijuan L; Martínez-Avilés L; Galván AB; Cañadas I; Rovira A; Zanui M; Martínez A; Longarón R; Sole F; Serrano S; Bellosillo B; Wynes MW; Albanell J; Hirsch FR; Arriola E
J Thorac Oncol; 2011 Jan; 6(1):21-7. PubMed ID: 21107285
[TBL] [Abstract] [Full Text] [Related]
